中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

48 records (took 0.017 seconds)

    Intraoral aversion devices and methods
    31.
    发明申请
    Intraoral aversion devices and methods 有权
    口腔内厌恶装置和方法

    公开(公告)号：US20050263160A1

    公开(公告)日：2005-12-01

    申请号：US10943379

    申请日：2004-09-17

    Applicant: David Utley ,  Jack Utley ,  Peter Keith ,  Michael Berman ,  Robert Atkinson

    Inventor： David Utley ,  Jack Utley ,  Peter Keith ,  Michael Berman ,  Robert Atkinson

    IPC: A24F47/00

    CPC classification number: A24F47/00

    Abstract: An intraoral aversion device to assist a user in quitting an undesirable behavior such as tobacco smoking, tobacco chewing, use of snuff, illicit drug use, excessive alcohol consumption, excessive food consumption, and/or other undesirable activity facilitated via the mouth. The aversion device may be wholly or partially configured to be disposed in the user's mouth, for example. The aversion device may include a detector and a output device, wherein the detector is configured to detect a parameter indicative of the user engaging in the habit or undesirable activity. If (and only if) the detector detects such a parameter, the output device delivers a negative stimulus to the user, thus providing negative feedback and creating an incentive for the user to limit if not eliminate the undesirable activity.

    Abstract translation: 口腔厌恶装置，用于帮助用户戒除诸如吸烟，烟草咀嚼，使用鼻烟，非法药物使用，过度饮酒，过度饮食消耗等不良行为和/或通过口促进的其他不良活动等不良行为。 例如，厌恶装置可以被全部或部分地配置为设置在使用者的口中。 厌恶装置可以包括检测器和输出装置，其中检测器被配置为检测指示用户参与习惯或不期望的活动的参数。 如果（且仅当）检测器检测到这样的参数，则输出设备向用户传送负激励，从而提供负反馈并且为用户创造激励以限制如果不消除不期望的活动。

    Method for treating fecal incontinence
    34.
    发明授权
    Method for treating fecal incontinence 有权
    治疗大便失禁的方法

    公开(公告)号：US07699844B2

    公开(公告)日：2010-04-20

    申请号：US11446771

    申请日：2006-06-05

    Applicant: David Utley ,  Scott West ,  John Gaiser ,  Rachel Croft

    Inventor： David Utley ,  Scott West ,  John Gaiser ,  Rachel Croft

    IPC: A61B18/18

    CPC classification number: A61B18/1477 ,  A61B1/31 ,  A61B18/1485 ,  A61B2018/00267 ,  A61B2018/00482 ,  A61B2018/00553 ,  A61B2018/00797 ,  A61B2018/0091 ,  A61B2018/00916 ,  A61B2018/046 ,  A61B2090/3782 ,  A61B2218/007

    Abstract: A sphincter tissue region is treated using a support structure sized for advancement into the anal canal. At least one electrode is carried by the structure. A mechanism is coupled to the electrode to move the electrode between a first position retracted in the support structure and a second position extended from the support structure through surface tissue to penetrate a subsurface tissue region at or near a sphincter in the anal canal. A cable is coupled to the electrode to conduct energy for application by the electrode to form a lesion in the subsurface tissue region.

    Abstract translation: 括约肌组织区域使用尺寸适合进入肛管的支撑结构来治疗。 该结构承载至少一个电极。 机构耦合到电极以在缩回到支撑结构中的第一位置和从支撑结构延伸穿过表面组织的第二位置之间移动电极，以穿透肛管内的括约肌处或附近的下表面组织区域。 电缆耦合到电极以传导电极施加的能量，以在地下组织区域中形成病变。

    Systems and methods for applying a selected treatment agent into contact with tissue
    35.
    发明申请
    Systems and methods for applying a selected treatment agent into contact with tissue 有权
    将选定的处理剂施用于与组织接触的系统和方法

    公开(公告)号：US20080033374A1

    公开(公告)日：2008-02-07

    申请号：US11906457

    申请日：2007-10-02

    Applicant: David Utley ,  John Gaiser ,  Rachel Croft

    Inventor： David Utley ,  John Gaiser ,  Rachel Croft

    IPC: A61M25/06 ,  A61M25/09

    CPC classification number: A61B18/1492 ,  A61B18/1477 ,  A61B2018/00214 ,  A61B2018/00232 ,  A61B2018/00553 ,  A61B2018/00797 ,  A61B2018/00815 ,  A61B2018/1425 ,  A61M25/0084

    Abstract: Systems and methods that treat disorders of the gastrointestinal tract by applying one or more treatment agents to tissue at or near the region where abnormal neurological symptoms or abnormal tissue conditions exist. The treatment agent is selected to either disrupt the abnormal nerve pathways and/or to alleviate the abnormal tissue conditions. The treatment agent can include at least one cytokine and/or at least one vanilloid compound to evoke a desired tissue response. The systems and methods can be used a primary treatment modality, or as a neoadjuvent or adjuvant treatment modality.

    Abstract translation: 通过将一种或多种治疗剂施用于存在异常神经症状或异常组织病状的区域处或附近的组织来治疗胃肠道疾病的系统和方法。 选择治疗剂以破坏异常神经通路和/或减轻异常组织状况。 治疗剂可以包括至少一种细胞因子和/或至少一种香草酸化合物以引起所需的组织应答。 系统和方法可以用作主要治疗方式，或作为新辅助治疗方式。

Patent Agency Ranking